Argenx's FB102 meets primary endpoint in Phase 2 celiac study; Vyvgart fails Sjögren's Phase 3 trial

Argenx's FB102 met its primary endpoint in a Phase 2 celiac disease study versus placebo with no new safety signals, and the company will advance the CD122 inhibitor into Phase 3. In a mixed pipeline update, Argenx's blockbuster drug Vyvgart failed to outperform placebo in a Phase 3 trial for Sjögren's disease, and the company ended the study.

Detected & updated continuously · Source: Nebula